[Wild-type gastroinestinal stromal tumors].

Area of Science:

• Oncology
• Gastroenterology
• Genetics

Background:

• Gastrointestinal stromal tumors (GIST) are the most common non-epithelial tumors of the GI tract.
• Wild-type GIST (WT-GIST) lacks activating mutations in tyrosine kinase receptor (Kit) and/or platelet-derived growth factor receptor A (PDGFRA).
• WT-GIST is a heterogeneous group with distinct molecular features and clinical associations.

Purpose of the Study:

• To review the molecular characteristics of WT-GIST.
• To summarize the therapeutic approaches for WT-GIST.
• To highlight the unique features of this rare GIST subtype.

Main Methods:

• Literature review of studies on WT-GIST.
• Analysis of genomic alterations in WT-GIST.
• Examination of clinical and therapeutic data for WT-GIST.

Main Results:

• WT-GIST is defined by the absence of Kit/PDGFRA mutations, but exhibits other genomic alterations like SDH deficiency or Ras pathway mutations.
• WT-GIST is associated with hereditary cancer syndromes, including Carney Triad and Neurofibromatosis Type 1 (NF1).
• Most WT-GIST subtypes are resistant to imatinib, necessitating alternative treatment strategies.

Conclusions:

• WT-GIST represents a distinct entity within GISTs, characterized by unique molecular drivers and clinical presentations.
• Understanding the molecular landscape of WT-GIST is crucial for developing effective therapeutic interventions.
• The management of WT-GIST differs significantly from conventional GISTs due to treatment resistance patterns.